Saturday, November 21, 2026
Advertise with us
Support us
Write for us
No Result
View All Result
claws
  • Home
  • About Us
    • Director General
    • Additional Director General
    • Jottings by Director General Emiritus
    • CLAWS Membership
    • Faculty
  • Publication
    • Web Articles
    • Issue Briefs
    • Manekshaw Papers
    • Newsletter
    • Essay
    • CLAWS Journal
    • Scholar Warrior
    • Books
    • Intern Articles
    • External Publications
  • Research Areas
    • Global & Regional Security
      • China
      • Pakistan
      • Afghanistan
      • South Asia
      • Indo Pacific
      • US, EU & Russia
      • MENA
      • CAR
    • National Security
      • National Security Strategy
      • Nuclear Deterrence
      • Non Traditional Threats
      • Intelligence
      • Terrorism & Internal Security
      • Grey Z & IW
      • Security Laws
    • Military Studies
      • Military Doctrine
      • Military Strategy
      • Peace Keeping Ops
      • Military History
      • Military Logistics
      • Out of Area Contingency Ops
      • Leadership
    • Military Technology & Defence Acquisition
      • Military Technology
      • Defence Acqn
      • Budgets & Finance
      • Defence Infrastructure
      • Human Resources
    • Multi Domain Studies
      • Jointmanship & Integration
      • Space
      • Cyber
      • Spl Operations
      • Energy & Environment
      • Defence Eco System
      • Defence Diplomacy
      • HADR
  • Web Archive
  • Events
    • Seminars
    • Webinars/RTD
  • PROMEX
  • University Cell
    • About The Initiative
    • Admission: Eligibility and Procedure
    • Guides | Supervisors in the PhD Programme:
    • Important Information
    • Administration
    • Application Fee: Batch – 10 Onwards
    • FEE STRUCTURE: 2026 BATCH – 9 ONWARDS
  • Careers
  • Contact
  • Home
  • About Us
    • Director General
    • Additional Director General
    • Jottings by Director General Emiritus
    • CLAWS Membership
    • Faculty
  • Publication
    • Web Articles
    • Issue Briefs
    • Manekshaw Papers
    • Newsletter
    • Essay
    • CLAWS Journal
    • Scholar Warrior
    • Books
    • Intern Articles
    • External Publications
  • Research Areas
    • Global & Regional Security
      • China
      • Pakistan
      • Afghanistan
      • South Asia
      • Indo Pacific
      • US, EU & Russia
      • MENA
      • CAR
    • National Security
      • National Security Strategy
      • Nuclear Deterrence
      • Non Traditional Threats
      • Intelligence
      • Terrorism & Internal Security
      • Grey Z & IW
      • Security Laws
    • Military Studies
      • Military Doctrine
      • Military Strategy
      • Peace Keeping Ops
      • Military History
      • Military Logistics
      • Out of Area Contingency Ops
      • Leadership
    • Military Technology & Defence Acquisition
      • Military Technology
      • Defence Acqn
      • Budgets & Finance
      • Defence Infrastructure
      • Human Resources
    • Multi Domain Studies
      • Jointmanship & Integration
      • Space
      • Cyber
      • Spl Operations
      • Energy & Environment
      • Defence Eco System
      • Defence Diplomacy
      • HADR
  • Web Archive
  • Events
    • Seminars
    • Webinars/RTD
  • PROMEX
  • University Cell
    • About The Initiative
    • Admission: Eligibility and Procedure
    • Guides | Supervisors in the PhD Programme:
    • Important Information
    • Administration
    • Application Fee: Batch – 10 Onwards
    • FEE STRUCTURE: 2026 BATCH – 9 ONWARDS
  • Careers
  • Contact
No Result
View All Result
CLAWS
No Result
View All Result
Home Articles

Biotechnology: India’s Emerging Instrument of Soft Power

Animesh SinghbyAnimesh Singh
November 20, 2026
in Articles
A A
0
Views: 141

Abstract

Health security is becoming inseparable from national security. Countries that can supply affordable medicines, vaccines and technical support now have an important form of influence that sits alongside economic and military power. India is well placed to use this advantage. Its pharmaceutical manufacturing base, vaccine capacity and experience of serving price-sensitive markets give it the means to support public health beyond its borders.

This article examines how India can turn that capability into a diplomatic capital. It compares India’s partnership-oriented model with China’s infrastructure-led approach, identifies the technological and institutional gaps that still hold India back, and sets out a practical agenda for research, manufacturing, regulation, skills and coordinated health diplomacy. The central argument is simple—when assistance is reliable, affordable, and designed to strengthen local systems, healthcare cooperation can create durable trust.

Power Without Pressure

Soft power is often described as the ability to persuade rather than compel. In practice, it grows when other countries see a nation as useful, credible, and dependable. Culture and political values matter, but so does the ability to solve real problems. Few problems are more immediate than access to medicines, diagnostics and vaccines.

The COVID-19 pandemic made this clear. It exposed fragile supply chains, unequal access to medical products, and the strategic cost of relying on a small number of suppliers. Health capacity moved from the margins of foreign policy to its centre. For India, this change created an opening to use an existing industrial strength in a more deliberate way.

India’s size has sometimes made its smaller neighbours wary of its intentions. Traditional tools of statecraft remain necessary, but they can also reinforce the idea that regional leadership is mainly about pressure and dominance. Healthcare cooperation offers a different language. A shipment of essential medicines, a training program for regulators or a long-term partnership between hospitals can demonstrate value without demanding political submission in return.

Why Biopharmaceuticals Matter

Biopharmaceuticals are medicines ‘made with biological processes and living systems rather than chemical synthesis alone’. The category includes vaccines, biosimilars, monoclonal antibodies and newer cell- and gene-based therapies. Developing and producing them requires more than factories. It depends on research platforms, skilled people, reliable cold chains, quality laboratories, and regulators that can work at international standards.

That combination of science, manufacturing, and public purpose is what makes the sector strategically important. A country that can deliver these products at scale can contribute to health security, support emergency response and build institutional relationships that endure long after a crisis has passed.

 Two Models of Medical Diplomacy

China’s overseas health engagement has often been linked to state financing and large, visible projects such as hospitals, diagnostic centres, pharmaceutical parks and equipment facilities. This can produce quick results, but systems built around Chinese technology, personnel and maintenance may also create long-term dependence. Questions about finance, data, servicing, and policy autonomy can follow.

India’s approach is generally less centres on turnkey infrastructure. Its comparative strength lies in affordable medicines, workforce training, regulatory cooperation, and links between institutions. The most useful version of this model works with a partner country’s existing health system and helps local organisations do more for themselves.

Table 1: A Simplified Comparison of the Two Approaches

DimensionChina-led ModelIndia-led Opportunity
Typical offerLarge infrastructure, equipment and integrated deliveryMedicines, training, regulation and institutional partnerships
Primary advantageSpeed, visibility and scaleAffordability, adaptability and local ownership
Main concernFinancial, technical or maintenance dependenceFragmented delivery and uneven follow-through
Strategic testCan projects remain sustainable after handover?Can India provide predictable, high-quality support at scale?

Where India Still Falls Short

India’s strength in generics does not automatically translate into leadership in advanced biologics. The country still has limited depth in novel drug discovery, sophisticated biologic platforms, and cell and gene therapies. Dependence on imported equipment, reagents, specialised chemicals and active ingredients also leaves the sector exposed when trade or logistics are disrupted.

Regulation remains another constraint. Multiple authorities, overlapping responsibilities and uneven coordination can slow research, approvals and commercial scale-up. Gaps in advanced manufacturing, testing laboratories and cold-chain infrastructure make it harder to respond quickly during emergencies or meet demanding export standards.

Research funding and the links between universities and industry also need attention. Strong science does not become a product on its own. Researchers, manufacturers, clinicians, regulators, and investors need practical routes for sharing risk and moving promising work from the laboratory into production.

Finally, health diplomacy itself is spread across several ministries and agencies. Without a common plan, medical exports, grants, training and emergency assistance can look like separate activities rather than parts of one long-term strategy.

Figure 1: Allocations

Why China Moved Faster

China identified biotechnology as a strategic industry early and supported it through long-term planning, public investment, research parks and large manufacturing clusters. Consistent funding, closer links between universities and firms, and a centralised system for project execution helped it build capability in innovative drugs and advanced platforms.

India followed a different path. Its success came mainly from generics, cost-efficient production, and export-led growth. That model created enormous value, but it did not require the same level of investment in original discovery or high-end biological platforms. The challenge now is not to abandon India’s affordability advantage, but to add deeper innovation to it.

A Practical Agenda for India

  • Invest in High-End Research. Build mission-led public-private centres for biologics and advanced therapies. Translational grants shared intellectual-property frameworks and technology partnerships can help research cross the gap between laboratory and market.
  • Secure Critical Inputs. Diversify suppliers of reagents, specialty chemicals and equipment; support domestic substitutes where feasible; and use long-term agreements or strategic reserves for inputs that cannot be replaced quickly.
  • Scale Manufacturing and Quality Infrastructure. Develop shared facilities, accredited testing laboratories, cold-chain capacity and well-governed clusters that meet international manufacturing standards.
  • Make Regulations Faster and More Coherent. Create a coordinated pathway for biologics, strengthen reviewer capacity, and pursue mutual recognition or regulatory cooperation with trusted partners without weakening safety standards.
  • Build the Talent Pipeline. Expand fellowships and industry-linked training for bioprocess engineers, clinical researchers and regulators. Curricula should reflect the skills that employers, and public agencies actually need.
  • Coordinate Health Diplomacy. A standing inter-agency unit could align exports, grants, technical assistance and emergency support, while setting clear rules for balancing overseas commitments with domestic needs.

Figure 2: Count Derived From the Ten Strategic Inputs Listed Above

The Supply-Chain Question

The input list in the original draft points to a significant concentration risk. China is identified as the dominant supplier or processor for seven out of the ten listed items, while India leads in mica and barytes. Australia and Brazil are listed for iron ore. This does not by itself measure market share or immediate vulnerability, but it illustrates why a biotechnology strategy cannot be separated from chemicals, minerals, equipment and trade policy.

Table 2: Strategic Inputs Reproduced

InputHealth or Industrial UseSupplier Named in Draft
BismuthGI medicines; intermediatesChina
FluorsparFluorinated APIs; specialty chemicalsChina
LithiumMedicines; fine chemicalsChina processing; Australia and Chile mining
Rare earthsImaging; diagnostics; catalystsChina
AntimonyCatalysts; intermediatesChina
Gallium and germaniumSensors; diagnostic devicesChina
Processed graphiteLaboratory equipment; electrodesChina
MicaTablet coatings; packagingIndia
BarytesX-ray contrast; chemicalsIndia
Iron oreMachinery; steel equipmentAustralia and Brazil; India is a major producer

Leadership Through Reliability

Biotechnology will not replace military, economic, or diplomatic power. It can, however, make India’s regional leadership more acceptable and useful. Affordable products matter, but reliability matters just as much. Partners will judge India by whether supplies arrive on time, quality remains consistent, training continues after announcements and cooperation survives changes in political attention.

This is where the idea of Vasudhaiva Kutumbakam can become more than a slogan. If India combines national capability with shared health security, it can align strategic interest with public benefit. The result would not be charity, nor an attempt to create dependence. It would be a network of countries that are better prepared because they have worked with India.

Conclusion

Healthcare has become an important field of international competition and cooperation. India already possesses many of the foundations needed to lead: a large pharmaceutical base, experience with affordable production and credibility across much of the developing world. Its opportunity is to move from being known mainly as a supplier to being valued as a long-term partner in health security.

That transition will require deeper research, stronger regulation, resilient supply chains, advanced manufacturing, and better coordination across government. It will also require discipline. External commitments must remain credible even when domestic pressures rise.

If India can meet that test, biotechnology may become one of its most effective instruments of statecraft. In an age of contested influence, medicines and medical partnerships can create something that coercion rarely lasts in trust.

Tags: BiopharmaceuticalsIndi-ChinaPandemicSoft Power Diplomacy
Previous Post

VIJAY: Force Multiplier in the Journey to Viksit Bharat

Animesh Singh

Animesh Singh

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Web Updates

Field Marshal Manekshaw Essay Competiton 2026

Promotion Exam Correspondence Pre Course (PROMEX)

Guidelines to Publish with CLAWS

Application Form – Study Mtrl for DSSC 2026

[NEW] Application Form for membership for PROMEX (PART B or D)

  • Trending
  • Comments
  • Latest
Russia-Ukraine War: Lessons from an Electronic Warfare (EW) Perspective

Russia-Ukraine War: Lessons from an Electronic Warfare (EW) Perspective

May 31, 2025
Field Marshal Manekshaw Essay Competiton 2026

Field Marshal Manekshaw Essay Competiton 2026

April 23, 2026
Results | Field Marshal Manekshaw Essay Competition – 2024

Field Marshal Manekshaw Essay Competiton 2025

May 23, 2025
The Silent High Ground: India’s Space Warfare Imperative

The Silent High Ground: India’s Space Warfare Imperative

October 1, 2026
The Silent High Ground: India’s Space Warfare Imperative

The Silent High Ground: India’s Space Warfare Imperative

34
From Sword Clashes to Drone Strikes: A History of Changing Battlefields

From Sword Clashes to Drone Strikes: A History of Changing Battlefields

15
The Arakan Army and Its Impact on India: Rising Tensions Along the Eastern Frontier 

The Arakan Army and Its Impact on India: Rising Tensions Along the Eastern Frontier 

5

Thwarting  Pakistan’s Nefarious Designs in Bangladesh

5
Biotechnology: India’s Emerging Instrument of Soft Power

Biotechnology: India’s Emerging Instrument of Soft Power

November 20, 2026
VIJAY: Force Multiplier in the Journey to Viksit Bharat

VIJAY: Force Multiplier in the Journey to Viksit Bharat

November 19, 2026
CLAWS – IIFOMAS ANNUAL SYMPOSIUM 2026

CLAWS – IIFOMAS ANNUAL SYMPOSIUM 2026

November 19, 2026
Financing the Garrison: Pakistan Military Insulates its Budget from the State’s Fiscal Collapse

Financing the Garrison: Pakistan Military Insulates its Budget from the State’s Fiscal Collapse

November 18, 2026

Popular Stories

  • Russia-Ukraine War: Lessons from an Electronic Warfare (EW) Perspective

    Russia-Ukraine War: Lessons from an Electronic Warfare (EW) Perspective

    0 shares
    Share 0 Tweet 0
  • Field Marshal Manekshaw Essay Competiton 2026

    0 shares
    Share 0 Tweet 0
  • Field Marshal Manekshaw Essay Competiton 2025

    0 shares
    Share 0 Tweet 0
  • The Silent High Ground: India’s Space Warfare Imperative

    0 shares
    Share 0 Tweet 0
  • Op Sindoor 2.0: Why & How India Must Prepare for the Next Round?

    0 shares
    Share 0 Tweet 0

About us

CLAWS

The Centre for Land Warfare Studies (CLAWS), New Delhi, India is an independent think tank on strategic studies and land warfare. The mandate of CLAWS covers national security issues, conventional military operations and sub-conventional warfare.

Browse by Category

  • Articles
  • Autumn 2019
  • Autumn 2020
  • Books
  • Chanakya Defence Dialogue
  • CLAWS Focus
  • CLAWS Journal
  • Essay
  • Events
  • External Publications
  • FMMEC
  • Intern Articles
  • Issue Briefs
  • Jottings by Director General Emiritus
  • Manekshaw Papers
  • Newsletter
  • Round Tables
  • Scholar Warrior
  • Seminars
  • Uncategorized
  • Web Updates
  • Winter 2019
  • YouTube Podcast

Recent News

Biotechnology: India’s Emerging Instrument of Soft Power

Biotechnology: India’s Emerging Instrument of Soft Power

November 20, 2026
VIJAY: Force Multiplier in the Journey to Viksit Bharat

VIJAY: Force Multiplier in the Journey to Viksit Bharat

November 19, 2026
  • Site Map
  • Tenders
  • Advertise With Us
  • Terms of use
  • Privacy Policy
  • Other Think Tanks

© 2008-2026 Centre for Land Warfare Studies (CLAWS).

No Result
View All Result
  • Home
  • About Us
    • Director General
    • Additional Director General
    • Jottings by Director General Emiritus
    • CLAWS Membership
    • Faculty
  • Publication
    • Web Articles
    • Issue Briefs
    • Manekshaw Papers
    • Newsletter
    • Essay
    • CLAWS Journal
    • Scholar Warrior
    • Books
    • Intern Articles
    • External Publications
  • Research Areas
    • Global & Regional Security
      • China
      • Pakistan
      • Afghanistan
      • South Asia
      • Indo Pacific
      • US, EU & Russia
      • MENA
      • CAR
    • National Security
      • National Security Strategy
      • Nuclear Deterrence
      • Non Traditional Threats
      • Intelligence
      • Terrorism & Internal Security
      • Grey Z & IW
      • Security Laws
    • Military Studies
      • Military Doctrine
      • Military Strategy
      • Peace Keeping Ops
      • Military History
      • Military Logistics
      • Out of Area Contingency Ops
      • Leadership
    • Military Technology & Defence Acquisition
      • Military Technology
      • Defence Acqn
      • Budgets & Finance
      • Defence Infrastructure
      • Human Resources
    • Multi Domain Studies
      • Jointmanship & Integration
      • Space
      • Cyber
      • Spl Operations
      • Energy & Environment
      • Defence Eco System
      • Defence Diplomacy
      • HADR
  • Web Archive
  • Events
    • Seminars
    • Webinars/RTD
  • PROMEX
  • University Cell
    • About The Initiative
    • Admission: Eligibility and Procedure
    • Guides | Supervisors in the PhD Programme:
    • Important Information
    • Administration
    • Application Fee: Batch – 10 Onwards
    • FEE STRUCTURE: 2026 BATCH – 9 ONWARDS
  • Careers
  • Contact

© 2008-2026 Centre for Land Warfare Studies (CLAWS).